Antihyperlipidemic Activity and Hematological Effects of Nigella Sativa Seeds Extract in Egg yolk-fed Rabbits: A Comparative Study with Atorvastatin.

Document Type : Original Article

Authors

1 Laboratory of Pharmacology and Toxicology, Institute of Veterinary Sciences, University of Mentouri Constantine 1, Algeria.

2 3Department of Nature and Life Sciences, Faculty of Sciences, University of 20 Août 1955, Skikda, Algeria.

3 GSPA Research Laboratory, Institute of Veterinary Sciences, University of Mentouri Constantine 1, Algeria

Abstract

The aim of this research work is to evaluate the antihyperlipemic activity of Nigella sativa L. seeds in the rabbit model by inducing hyperlipidemia by egg yolk. The study was carried out on 30 female rabbits divided into 5 groups of 6 each: The first received no treatment and served as a control (CRL), the second group was gavaged with the aqueous extract of the of nigella seeds (NS), the 3rd group was gavaged by the egg yolk only (EY), the 4th was gavaged by the egg yolk and treated by atorvastatin drug (EY+ATV) and the last group was gavaged with egg yolk and treated by black seed as NS (EY+NS). The different animal groups were treated for a period of 4 weeks. The haematological results showed a significant decrease at least at P≤0.05 in hemoglobin, red blood cells and platelets number in EY and EY+ATV groups compared to CRL or to EY+NS groups. The biochemical results showed that administration of egg yolk in the EY group caused an increase in total cholesterol (TC), LDL (Low Density Lipoproteins) cholesterol, as well as triglycerides (TG). The 2 groups (EY+ATV) and (EY+NS) registered a marked decrease in TC, LDL and TG and an increase in HDL cholesterol (High Density Lipoproteins). From the obtained results in this work, it can be concluded that the seeds of Nigella sativa may exert antihyperlipemic activity.

Keywords


Volume 66, Issue 13 - Serial Number 13
Special Issue: Applied Chemistry for Greener Life and Sustainability
December 2023
Pages 1479-1487
  • Receive Date: 27 December 2022
  • Revise Date: 24 March 2023
  • Accept Date: 02 June 2023